Cover Image
市場調查報告書

Seattle Genetics, Inc.:產品平台分析

Seattle Genetics, Inc. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 251721
出版日期 內容資訊 英文 65 Pages
訂單完成後即時交付
價格
Back to Top
Seattle Genetics, Inc.:產品平台分析 Seattle Genetics, Inc. - Product Pipeline Review - 2015
出版日期: 2015年03月31日 內容資訊: 英文 65 Pages
簡介

Seattle Genetics, Inc.ha是使用單株抗體開發癌症治療藥的生物醫藥品企業。

本報告提供Seattle Genetics, Inc.的治療藥開發平台現狀及各開發階段的比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,彙整最新的企業新聞和發表,後期階段及中止的計劃相關資訊等。

Seattle Genetics, Inc.的基本資料

Seattle Genetics, Inc.概要

  • 主要資訊
  • 企業資料

Seattle Genetics, Inc.:R&D概要

  • 主要的治療範圍

Seattle Genetics, Inc.:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式

Seattle Genetics, Inc.:開發中產品概況

  • 最後階段的開發中產品
    • 第三階段的產品/聯合治療模式
  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式

Seattle Genetics, Inc.:藥物簡介

  • brentuximab vedotin
  • SGN-CD19A
  • SGN-CD33A
  • SGN-LIV1A
  • SGD-2083
  • SGN-CD70A

Seattle Genetics, Inc.:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Seattle Genetics, Inc.:最近的開發平台趨勢

Seattle Genetics, Inc.:暫停中的計劃

Seattle Genetics, Inc.:開發中止的開發中產品

  • 開發中止的開發中產品簡介
    • dacetuzumab
    • lintuzumab
    • SGN-15
    • vorsetuzumab
    • vorsetuzumab mafodotin

Seattle Genetics, Inc.:企業發表

Seattle Genetics, Inc.:總公司和子公司的所在地

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC06877CDB

Summary

Global Markets Direct's, 'Seattle Genetics, Inc. - Product Pipeline Review - 2015', provides an overview of the Seattle Genetics, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Seattle Genetics, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Seattle Genetics, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Seattle Genetics, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Seattle Genetics, Inc.'s pipeline products

Reasons to buy

  • Evaluate Seattle Genetics, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Seattle Genetics, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Seattle Genetics, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Seattle Genetics, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Seattle Genetics, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Seattle Genetics, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Seattle Genetics, Inc. Snapshot
  • Seattle Genetics, Inc. Overview
    • Key Information
    • Key Facts
  • Seattle Genetics, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Seattle Genetics, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • Seattle Genetics, Inc. - Pipeline Products Glance
    • Seattle Genetics, Inc. - Late Stage Pipeline Products
      • Pre-Registration Products/Combination Treatment Modalities
      • Phase III Products/Combination Treatment Modalities
    • Seattle Genetics, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Seattle Genetics, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Seattle Genetics, Inc. - Drug Profiles
    • brentuximab vedotin
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • denintuzumab mafodotin
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SEA-CD40
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SGN-CD33A
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SGN-CD70A
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SGN-LIV1A
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SGD-2083
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Seattle Genetics, Inc. - Pipeline Analysis
    • Seattle Genetics, Inc. - Pipeline Products by Target
    • Seattle Genetics, Inc. - Pipeline Products by Route of Administration
    • Seattle Genetics, Inc. - Pipeline Products by Molecule Type
    • Seattle Genetics, Inc. - Pipeline Products by Mechanism of Action
  • Seattle Genetics, Inc. - Recent Pipeline Updates
  • Seattle Genetics, Inc. - Dormant Projects
  • Seattle Genetics, Inc. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • dacetuzumab
      • lintuzumab
      • SGN-15
      • vorsetuzumab
      • vorsetuzumab mafodotin
  • Seattle Genetics, Inc. - Company Statement
  • Seattle Genetics, Inc. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Seattle Genetics, Inc., Key Information
  • Seattle Genetics, Inc., Key Facts
  • Seattle Genetics, Inc. - Pipeline by Indication, 2015
  • Seattle Genetics, Inc. - Pipeline by Stage of Development, 2015
  • Seattle Genetics, Inc. - Monotherapy Products in Pipeline, 2015
  • Seattle Genetics, Inc. - Partnered Products in Pipeline, 2015
  • Seattle Genetics, Inc. - Partnered Products/ Combination Treatment Modalities, 2015
  • Seattle Genetics, Inc. - Pre-Registration, 2015
  • Seattle Genetics, Inc. - Phase III, 2015
  • Seattle Genetics, Inc. - Phase II, 2015
  • Seattle Genetics, Inc. - Phase I, 2015
  • Seattle Genetics, Inc. - Preclinical, 2015
  • Seattle Genetics, Inc. - Pipeline by Target, 2015
  • Seattle Genetics, Inc. - Pipeline by Route of Administration, 2015
  • Seattle Genetics, Inc. - Pipeline by Molecule Type, 2015
  • Seattle Genetics, Inc. - Pipeline Products by Mechanism of Action, 2015
  • Seattle Genetics, Inc. - Recent Pipeline Updates, 2015
  • Seattle Genetics, Inc. - Dormant Developmental Projects,2015
  • Seattle Genetics, Inc. - Discontinued Pipeline Products, 2015
  • Seattle Genetics, Inc., Subsidiaries

List of Figures

  • Seattle Genetics, Inc. - Pipeline by Top 10 Indication, 2015
  • Seattle Genetics, Inc. - Pipeline by Stage of Development, 2015
  • Seattle Genetics, Inc. - Monotherapy Products in Pipeline, 2015
  • Seattle Genetics, Inc. - Partnered Products in Pipeline, 2015
  • Seattle Genetics, Inc. - Pipeline by Top 10 Target, 2015
  • Seattle Genetics, Inc. - Pipeline by Top 10 Route of Administration, 2015
  • Seattle Genetics, Inc. - Pipeline by Top 10 Molecule Type, 2015
  • Seattle Genetics, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top